Search research articles
Contact Us
Filters
Showing results (101-110 of 107) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 107 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J McGee, M Bookman, P Harter, et al.
Journal of the National Cancer Institute
|
October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel
P Hoskins, I Vergote, A Cervantes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander, J Rau, C K Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 17, 2010
Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study
J Martin-Broto, A Gutierrez, X Garcia-Del-Muro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 14, 2016
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group
A Gronchi, S Stacchiotti, P Verderio, et al.
British Journal of Cancer
|
February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
N Colombo, A Gadducci, J Sehouli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
F H van Wijk, M S Aapro, G Bolis, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 107) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 107 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J McGee, M Bookman, P Harter, et al.
Journal of the National Cancer Institute
|
October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel
P Hoskins, I Vergote, A Cervantes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander, J Rau, C K Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 17, 2010
Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study
J Martin-Broto, A Gutierrez, X Garcia-Del-Muro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 14, 2016
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group
A Gronchi, S Stacchiotti, P Verderio, et al.
British Journal of Cancer
|
February 9, 2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
N Colombo, A Gadducci, J Sehouli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
F H van Wijk, M S Aapro, G Bolis, et al.
Page
of 11